Conversely, among patients with TP53-mutated ts-AML, outcomes were inferior with HMA plus venetoclax as compared with IC/LIT without venetoclax (median OS 2.8 months vs. 3.5 months; 1-year OS rate 3% vs. 0%; P = 0.06). This evidence concerns the gene TP53 and acute myeloid leukemia.